Good Genes
Banking on biotech, this innovator sees a cleaner future in enzymes.
In the late 1970s, Mark Emalfarb used $5,000 to start a company that revolutionized the world of blue jeans by introducing the process of stonewashing with pumice stones to other companies in the United States. Now Emalfarb, 51, and Dyadic International Inc. in Jupiter, Florida, are moving from jeans to genes. Using enzymes that are derived from a Russian fungus, they're developing a system for gene discovery and manufacturing that will result in new, affordable medicines.
Dyadic has found other uses for the enzymes, too. Emalfarb originally sought their development when the blue-jean industry shifted from pumice to chemicals. He realized the enzymatic action softening the cotton in his jeans might also break down other plant materials. The $15.8 million company now creates enzymes for pulp and paper mills to make the process cleaner and more efficient, and it's currently testing its enzymes on ethanol production from corn byproducts. Says Emalfarb, "We can make 810 million gallons of ethanol from last year's byproduct alone."
Continue reading this article - and everything on Entrepreneur!
Become a member to get unlimited access and support the voices you want to hear more from. Get full access to Entrepreneur for just $5.
Entrepreneur Editors' Picks
-
This Co-Founder Was Kicked Out of Retailers for Pitching a 'Taboo' Beauty Product. Now, Her Multi-Million-Dollar Company Sells It for More Than $20 an Ounce.
-
Have You Ever Obsessed Over 'What If'? According to Scientists, You Don't Actually Know What Would Have Fixed Everything.
-
After He Was Fired From the UFC, This Former Fighter Turned His Passion Into a Thriving Business
-
Most People Don't Know These 2 Things Are Resume Red Flags. A Career Expert Reveals How to Work Around Them.
-
How One Woman Turned Pandemic-Induced Boredom and a Makeshift Garage Art Studio Into a Thriving Franchise
-
Use These 4 Self-Care Rituals for More Resilience and Less Depletion
-
Shark Tank's Barbara Corcoran Wants to Invest in 'Someone Who Probably Needs a Good Shrink Instead of a Business'